Blood Banking.. • PCs can be prepared from whole blood by centrifugation by the PRP method (United States) or by the buffy coat method. These platelet concentrates can be prepared to be pre-storage leukoreduced by filtration. • A PC should contain a minimum of 5.5 x 10^10 platelets (in 90% of the sampled units according to AABB Standards) in a volume routinely between 45 and 65 mL that is sufficient to maintain a pH of 6.2 or greater at the conclusion of the 5-day storage period. • When PCs (usually 4–6) are pooled as a transfusible product/dose, the storage time changes to 4 hours. There is the thought that pools could be stored up to the time of outdating in conjunction with testing for bacterial contamination and the use of sterile docking to prepare the pools. • Platelets are increasingly being prepared by apheresis using cell separators that can produce leukocytereduced products during the separation process or by subsequent filtration (depending on the cell separator). • Apheresis components contain 4–6 times as many platelets as a PC prepared from whole blood. They should contain a minimum of 3.0 x 10^11 platelets (in 90% of the sampled units). • When appropriate and possible, apheresis procedures are harvesting from healthy donors enough platelets to prepare two unique products by division by weight (splitting), each with a minimum of 3.0 x 10^11 platelets. • Platelet components are stored for up to 5 days at 20°–24°C with continuous agitation. When necessary, as during shipping, platelets can be stored without continuous agitation for up to 24 hours (at 20°–24°C) during a 5-day storage period. Platelets are rarely stored at 1°–6°C. • If a platelet bag is broken or opened, the platelets must be transfused within 4 hours when stored at 20°–24°C. • Research is being conducted in many areas relating to the preparation and storage of platelets. These include documentation that platelets can be stored for up to 7 days at 20°–24°C with current technologies, development of procedures to reduce/inactivate any residual pathogens, development of additive (synthetic) solutions, and the development of platelet substitute products. admin: M-Sultan
Posted on: Tue, 17 Sep 2013 11:17:38 +0000